Search This Blog

Thursday, July 23, 2026

J&J positive Phase 3 MonumenTAL-6 data for combo in relapsed/refractory multiple myeloma

 

Johnson & Johnson reports positive Phase 3 MonumenTAL-6 data for TECVAYLI plus TALVEY in earlier-line relapsed/refractory multiple myeloma

  • Topline MonumenTAL-6 data show TECVAYLI plus TALVEY significantly improved progression-free and overall survival versus standard-of-care regimens.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)